Tower Research Capital LLC TRC Reduces Stock Position in bluebird bio, Inc. (NASDAQ:BLUE)

Tower Research Capital LLC TRC decreased its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 79.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,077 shares of the biotechnology company’s stock after selling 12,032 shares during the quarter. Tower Research Capital LLC TRC’s holdings in bluebird bio were worth $26,000 at the end of the most recent quarter.

Separately, Barclays PLC grew its holdings in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 184,605 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Price Performance

Shares of NASDAQ:BLUE opened at $4.97 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio, Inc. has a 1 year low of $3.20 and a 1 year high of $28.60. The stock has a market capitalization of $48.66 million, a P/E ratio of -0.13 and a beta of 0.27. The stock has a 50-day simple moving average of $4.25 and a 200-day simple moving average of $6.31.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Wells Fargo & Company lowered their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. StockNews.com assumed coverage on bluebird bio in a report on Thursday. They issued a “sell” rating for the company. Barclays lowered their price target on bluebird bio from $40.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, March 31st. Finally, JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, bluebird bio presently has a consensus rating of “Hold” and an average price target of $44.60.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.